These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17339744)

  • 41. Adherence to K/DOQI practice guidelines for bone metabolism and disease.
    Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W
    Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients.
    Hamida FB; Fatma LB; Barbouch S; Kaaroud H; Helal I; Hedri H; Abdallah TB; Maiz HB; Kheder A
    Saudi J Kidney Dis Transpl; 2008 Mar; 19(2):183-8. PubMed ID: 18310864
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of dialysate calcium concentration in hemodialysis.
    Toussaint N; Cooney P; Kerr PG
    Hemodial Int; 2006 Oct; 10(4):326-37. PubMed ID: 17014507
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nonphosphate-binding effects of sevelamer--are they of clinical relevance?
    Marangon N; Lindholm B; Stenvinkel P
    Semin Dial; 2008; 21(5):385-9. PubMed ID: 18573137
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost of applying the K/DOQI guidelines for bone metabolism and disease to a cohort of chronic hemodialysis patients.
    White CA; Jaffey J; Magner P
    Kidney Int; 2007 Feb; 71(4):312-7. PubMed ID: 17183248
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Control of calcium and phosphate metabolism and prevention of vascular calcifications in uremic patients].
    Malberti F; Ravani P
    G Ital Nefrol; 2005; 22 Suppl 31():S47-52. PubMed ID: 15786402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Sevelamer hydrochloride and vitamin D for controlling serum calcium, phosphorus and bone metabolism in patients undergoing hemodialysis].
    Ishida M; Yao N; Yachiku S; Anzai T; Kobayashi T; Ishida H
    Clin Calcium; 2005 Sep; 15 Suppl 1():192-9. PubMed ID: 16279024
    [No Abstract]   [Full Text] [Related]  

  • 49. Calcium and phosphorus control in patients undergoing hemodialysis: from the view-points of activities of daily living.
    Osawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S54-61. PubMed ID: 17976087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Japanese Society of Dialysis Therapy treatment guidelines for secondary hyperparathyroidism.
    Kazama JJ
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S44-7. PubMed ID: 17976085
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Experimental study of the mechanism for vascular calcification in chronic kidney disease].
    Persy V
    Verh K Acad Geneeskd Belg; 2008; 70(4):285-303. PubMed ID: 19166100
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Disturbances of mineral metabolism and vascular calcifications in dialysis patients (review)].
    Malberti F; Ravani P
    G Ital Nefrol; 2004; 21(3):238-44. PubMed ID: 15285002
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sevelamer therapy for pediatric end-stage renal disease.
    Storms LE; Chicella MF; Dice JE
    Pharmacotherapy; 2006 Mar; 26(3):410-3. PubMed ID: 16503722
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Defining the role of sevelamer chloride as a therapeutic agent for management of phosphate in patient with hemodialysis].
    Hashimoto N; Miyata M; Sato N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():30-4; discussion 34. PubMed ID: 16272626
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients.
    Monge M; Shahapuni I; Oprisiu R; El Esper N; Morinière P; Massy Z; Choukroun G; Fournier A
    Nat Clin Pract Nephrol; 2006 Jun; 2(6):326-36. PubMed ID: 16932454
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Vascular calcification and ESRD: a hard target.
    Bhan I; Thadhani R
    Clin J Am Soc Nephrol; 2009 Dec; 4 Suppl 1():S102-5. PubMed ID: 19995990
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Role of sevelamer hydrochloride in the Coronary Artery Calcification Index].
    Tsuruta Y; Kaneshiro K; Narita Y; Oobayashi T; Fujii M; Narita M; Sasai K; Yoshimata T; Watanabe Y; Maeda K
    Clin Calcium; 2005 Sep; 15 Suppl 1():200-5. PubMed ID: 16279025
    [No Abstract]   [Full Text] [Related]  

  • 58. [Vitamin D, cardiovascular disease and mortality in patients with kidney disease].
    Hansen D; Brandi L; Rasmussen K
    Ugeskr Laeger; 2009 Dec; 171(50):3684-9. PubMed ID: 20003863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathophysiological aspects of vascular calcification in chronic renal failure.
    Drüeke TB
    Nefrologia; 2005; 25 Suppl 2():96-9. PubMed ID: 16050411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Contributions of the software La Clé Concerto in the implementation of the NKF-K/DOQI (National Kidney Foundation-Kidney/Dialysis Outcomes Quality Initiative) recommendations for the control of mineral and bone metabolism disorders in the patient with chronic renal failure].
    Ureña P
    Nephrol Ther; 2008 Sep; 4 Spec No 1():9-14, 20-35. PubMed ID: 19031633
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.